MRL is dead

Quote






Ken, Roger and VPs, if you don't wake up soon, then do us a favor and time to retire. You're success is blinding you and it will come back to haunt everyone else while you ride off into the sunset with your stock options and multi-million dollar salaries. You've got to learn to multitask and in-license good compounds to supplement internal pipeline. You can't just rely on Keytruda. Bring back Vagelos

In-license deal signed only 4 years ago with big payback.
Galapagos RI drug


anonymous said:
Vagelos was the best thing that happened to Merck. Scolnick thought he was the smartest man in any room. Gilmartin did not have a clue. Fraser slashed and burned the heart and soul of the Company I loved so much. I think i kissed the ground the first day I started working in Rahway in 1980. I met all these guys including Horan who was before Vagelos. Vagelos was head and tails above the rest.
Click to expand...
 






anonymous said:
Ken, Roger and VPs, if you don't wake up soon, then do us a favor and time to retire. You're success is blinding you and it will come back to haunt everyone else while you ride off into the sunset with your stock options and multi-million dollar salaries. You've got to learn to multitask and in-license good compounds to supplement internal pipeline. You can't just rely on Keytruda. Bring back Vagelos

In-license deal signed only 4 years ago with big payback.
Galapagos RI drug
Click to expand...

Firstly, there is no internal pipeline, hasn’t been one for well over a decade, never will there be one. Secondly, they don’t care because they will be long gone before Keytruda patent expires.
 






NGM will help fill the pipeline...
Concerning there is leadership turnover if this is such a good place to work, doesn't pass the smell test.
NGM pharmaceutical
Only started this collaboration in 2015 and it needs time to produce

$450million plus payments on any compound that succeeds in the clinic
Merck & NGM agreement

anonymous said:
Firstly, there is no internal pipeline, hasn’t been one for well over a decade, never will there be one. Secondly, they don’t care because they will be long gone before Keytruda patent expires.
Click to expand...
 




































What are RY, WP or legacy Boston R&D sites doing? Not worthy of mention by Ken on the earnings call.
WTF??

earnings call transcript

There is also impressive work underway in our discovery hubs in Cambridge, London, and
South San Francisco, where we are incorporating some of the most scientifically
advanced modalities and technologies in the world. Importantly, these hubs are located
where many of the best biotech and scientific mines are gathered. And we're benefiting
from the vibrant academics and biotech communities in each of our respective hub.


anonymous said:
Same here. Long live Keytruda!
Click to expand...
 






anonymous said:
What are RY, WP or legacy Boston R&D sites doing? Not worthy of mention by Ken on the earnings call.
WTF??

earnings call transcript

There is also impressive work underway in our discovery hubs in Cambridge, London, and
South San Francisco, where we are incorporating some of the most scientifically
advanced modalities and technologies in the world. Importantly, these hubs are located
where many of the best biotech and scientific mines are gathered. And we're benefiting
from the vibrant academics and biotech communities in each of our respective hub.
Click to expand...

“scientific mines”...you mean scientific minds. No wonder you can’t discover drugs, you can’t even spell!
 






Anonymous said:
With all due respect to your naivete, surely you cannot be serious! Did you have the impression that MRL (or all of Merck for that matter) is some kind of "democracy"? LOL. Where opposing viewpoints are respected and considered? Where thoughtful difference of opinion or helpful suggestions were/are encouraged? Think North Korea, my friend. Three or four autocrats with limitless power and arrogance, and no accountability. And everyone else better march to their drums....or you're out on the street. Speaking up has always been/is suicide. At least for the past 8 years. That's why the really good, respected scientists voted with their feet. All that is left are 1) the handful of VPs who are given free reign to repeat the same mistakes over and over, 2) the yes-men and yes-women who are the Lean-Sigma and 5S enforcers, flooding everyone with stifling, unending process, and 3) the terrified bench scientists who have their hands chained, and dare not let out a peep. They know what happens to those that "peep".

RP has done nothing in this regard. The corrupt VP process-drivers and destroyers of research are still alive and well. It's no secret why innovation is dead and the pipeline has gone to sh!t.
Click to expand...

Scientists don’t have hands chained, more like final 5 minutes of Braveheart. FRRREEEEEDOMMMMMMMM!
 






anonymous said:
What are RY, WP or legacy Boston R&D sites doing? Not worthy of mention by Ken on the earnings call.
WTF??

earnings call transcript

There is also impressive work underway in our discovery hubs in Cambridge, London, and
South San Francisco, where we are incorporating some of the most scientifically
advanced modalities and technologies in the world. Importantly, these hubs are located
where many of the best biotech and scientific mines are gathered. And we're benefiting
from the vibrant academics and biotech communities in each of our respective hub.
Click to expand...

London is the new hotness. move over SSF! Don’t need to actually DO anything just be near the “best scientific minds” and pose for photo shoots with VP.
 
























Tilos LAP target

QUOTE="anonymous, post: 6168640"]Merck Senior Management
You missed the boat this week at the JP Morgan conference.
Look at cellular therapy: autologous CART or allogeneic CART

You are behind!!! You need to look for a few key additions and not just focus on Keytruda.
Novartis is leader and now Bristol has a leg up on you.
WAKE UP!!![/QUOTE]
 






anonymous said:
Tilos LAP target

QUOTE="anonymous, post: 6168640"]Merck Senior Management
You missed the boat this week at the JP Morgan conference.
Look at cellular therapy: autologous CART or allogeneic CART

You are behind!!! You need to look for a few key additions and not just focus on Keytruda.
Novartis is leader and now Bristol has a leg up on you.
WAKE UP!!!
Click to expand...
[/QUOTE]
Probably the same idiot who asks about this every damn R&D town hall....
 


















Top Bottom
Back
Quote